

## **KURZPROTOKOLL** **DESIREE**

<b>Öffentlicher Titel</b>	Phase II Studie zur einschleichenden Dosierung von Everolimus bei metastasiertem Brustkrebs
<b>Wissenschaftl. Titel</b>	Eine multizentrische, randomisierte doppelblinde, Phase-II-Studie zum Vergleich der Verträglichkeit bei einschleichender Dosierung von Everolimus bei Patientinnen mit metastasiertem Brustkrebs
<b>Kurztitel</b>	DESIREE
<b>Studienart</b>	multizentrisch, Therapiestudie, randomisiert, doppelblind, zweiarmig
<b>Studienphase</b>	Phase II
<b>Erkrankung</b>	Geschlechtsorgane: Brustkrebs: Zweitlinie oder höher
<b>Ziele</b>	<ul style="list-style-type: none"><li>- To compare the cumulative rate of mucositis/stomatitis grade 2-4 (WHO's oral toxicity scale (OTS)) at 12 weeks after start of treatment using a conventional and a dose-escalating schema of everolimus in combination with exemestane in patients with metastatic breast cancer and progression or relapse after non-steroidal aromatase-inhibitor treatment.</li></ul>
<b>Einschlusskriterien</b>	<ul style="list-style-type: none"><li>- Locally advanced or metastatic stage of disease not amenable to curative treatment by surgery or radiotherapy alone.</li><li>- No indication for chemotherapy (e.g. symptomatic visceral metastasis)</li><li>- Histological confirmed hormone receptor-positive (HR+), HER2-negative carcinoma of the breast.</li><li>- Postmenopausal women</li><li>- Disease progression following prior therapy with non steroidal aromatase inhibitors (NSAI), defined as: a. Recurrence while on, or following completion of an adjuvant treatment with Letrozole or Anastrozole, or b. Progression while on or following completion of Letrozole or Anastrozole treatment for ABC/MBC. Note: Non-steroidal aromatase inhibitors (i.e. Letrozole or Anastrozole) do not have to be the last treatment prior to enrollment. Other prior anticancer therapy, e.g. Tamoxifen, Fulvestrant, Exemestane, is also allowed. Patients must have recovered to grade 1 or better from any adverse events (except alopecia) related to previous therapy prior to enrollment.</li><li>- At least 4 weeks since radiotherapy, with full recovery. The measurable disease must be completely outside the radiation field or there must be pathologic proof of newly progressive disease.</li></ul>
<b>Ausschlusskriterien</b>	<ul style="list-style-type: none"><li>- Concurrent immunotherapy or hormonal therapy (contraceptive and/or replacement therapy). Bisphosphonates or denosumab may be continued or started before randomization.</li><li>- Life expectancy of less than 3 months.</li><li>- Parenchymal brain metastases, unless adequately controlled by surgery and/or radiotherapy.</li><li>- Any ongoing toxicity from prior anti-cancer therapy that is grade 3-4 and/or that is progressing in severity, except alopecia or anemia controlled by growth factors.</li><li>- Known or suspected congestive heart failure (&gt;NYHA I) and/or coronary heart disease, angina pectoris requiring anti-anginal medication, previous history of myocardial infarction 6months, evidence of transmural infarction on ECG, un- or poorly controlled arterial hypertension (i.e. BP &gt;150/100 mmHg under treatment with two antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease.</li><li>- Currently active infection.</li><li>- History of other malignancies within the last 5 years which significantly affect the diagnosis, assessment or prognosis of metastatic breast cancer.</li><li>- Malabsorption syndrome or insufficient gastrointestinal function, preexisting diagnosis of ulcerative colitis.</li></ul>

**KURZPROTOKOLL  
DESIREE**

- Concurrent treatment with other experimental drugs; participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.
- Insufficiently controlled diabetes, known HIV infection or chronic hepatitis B or C and seriously impaired liver function (Child-Pugh, class A, B or C).

**Alter** 18 Jahre und älter

**Molekularer Marker** HER2/neu neg./ER pos.  
HER2/neu neg./PR pos.

**Fallzahl** 156

**Prüfzentren** **Sana Klinikum Offenbach** (Rekrutierung beendet)

Starkenburgring 66  
63069 Offenbach  
Benjamin Schnappauf  
Tel: 069 8405-7032  
Fax: 069 8405-4486  
[benjamin.schnappauf@sana.de](mailto:benjamin.schnappauf@sana.de)

**Agaplesion Markus Krankenhaus** (Rekrutierung beendet)  
Wilhelm-Epstein-Straße 4  
60431 Frankfurt am Main  
Madeleine Modrow  
Tel: 069 953366754  
Fax: 069 95338916754  
[madeleine.modrow@fdk.info](mailto:madeleine.modrow@fdk.info)

**Klinikum Hanau GmbH** (Rekrutierung beendet)  
Klinik für Gynäkologie und Geburtshilfe  
Leimenstraße 20  
63450 Hanau  
PD. Dr. med. Thomas Müller  
Tel: 06181 296-2500  
Fax: 06181 296-2540  
[linikgynggeb@klinikum-hanau.de](mailto:linikgynggeb@klinikum-hanau.de)

**Sponsor** German Breast Group

**Registrierung in anderen Studienregistern** EudraCT 2014-005126-35  
ClinicalTrials.gov NCT02387099